Pacific Biosciences Of California (PACB) FCF Margin (2010 - 2026)
Pacific Biosciences Of California's quarterly FCF Margin came in at 128.39% in Q1 2026, down 607.0% year-on-year from 25.32% in Q1 2025, and down 187.61% quarter-over-quarter from 44.64% in Q4 2025.
Pacific Biosciences Of California has reported FCF Margin for 17 years, with the latest figure at 128.39% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 607.0% year-over-year to 128.39%; the trailing twelve-month figure through Mar 2026 stood at 72.62% (up 4430.0% YoY), and the FY2025 full-year result was 71.2%, up 6661.0% from the prior year.
- FCF Margin for Q1 2026 stood at 128.39%, down from 44.64% in the prior quarter.
- The five-year high for FCF Margin was 44.64% in Q4 2025, with the low at 252.99% in Q1 2023.
- Average FCF Margin over 5 years is 142.22%, with a median of 122.32% recorded in 2025.
- Year-over-year, FCF Margin plunged 16814 bps in 2022 and jumped 13725 bps in 2023.
- Tracing PACB's FCF Margin over 5 years: stood at 239.35% in 2022, then soared by 57 bps to 102.1% in 2023, then rose by 19 bps to 82.26% in 2024, then surged by 46 bps to 44.64% in 2025, then plunged by 188 bps to 128.39% in 2026.
- The last three FCF Margin figures came in at 128.39% (Q1 2026), 44.64% (Q4 2025), and 48.44% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1.28% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 37.67% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 3.98% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.44% |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | -128.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.39% |
| Dec 31, 2025 | -44.64% |
| Sep 30, 2025 | -48.44% |
| Jun 30, 2025 | -75.26% |
| Mar 31, 2025 | -122.32% |
| Dec 31, 2024 | -82.26% |
| Sep 30, 2024 | -111.78% |
| Jun 30, 2024 | -154.78% |
| Mar 31, 2024 | -205.00% |
| Dec 31, 2023 | -102.10% |
| Sep 30, 2023 | -118.53% |
| Jun 30, 2023 | -92.51% |
| Mar 31, 2023 | -252.99% |
| Dec 31, 2022 | -239.35% |
| Sep 30, 2022 | -208.11% |
| Jun 30, 2022 | -182.09% |
| Mar 31, 2022 | -249.20% |
| Dec 31, 2021 | -95.92% |
| Jun 30, 2021 | -56.46% |
| Mar 31, 2021 | -81.06% |
| Dec 31, 2020 | -52.81% |
| Sep 30, 2020 | -96.13% |
| Jun 30, 2020 | -141.17% |
| Mar 31, 2020 | 482.41% |
| Dec 31, 2019 | -65.60% |
| Sep 30, 2019 | -82.54% |
| Jun 30, 2019 | -73.81% |
| Mar 31, 2019 | -161.74% |
| Dec 31, 2018 | -97.53% |
| Sep 30, 2018 | -78.58% |
| Jun 30, 2018 | -73.47% |
| Mar 31, 2018 | -98.73% |
| Dec 31, 2017 | -85.26% |
| Sep 30, 2017 | -89.59% |
| Jun 30, 2017 | -80.99% |
| Mar 31, 2017 | -77.62% |
| Dec 31, 2016 | -60.46% |
| Sep 30, 2016 | -72.37% |
| Jun 30, 2016 | -104.51% |
| Mar 31, 2016 | -108.35% |
| Dec 31, 2015 | -4.39% |
| Sep 30, 2015 | -116.61% |
| Jun 30, 2015 | -33.88% |
| Mar 31, 2015 | -139.57% |
| Dec 31, 2014 | -93.67% |
| Sep 30, 2014 | -31.15% |
| Jun 30, 2014 | -123.28% |
| Mar 31, 2014 | -143.73% |
| Dec 31, 2013 | -160.67% |
| Sep 30, 2013 | 249.20% |
| Jun 30, 2013 | -275.91% |
| Mar 31, 2013 | -320.40% |
| Dec 31, 2012 | -317.51% |
| Sep 30, 2012 | -653.13% |
| Jun 30, 2012 | -330.81% |
| Mar 31, 2012 | -175.45% |
| Dec 31, 2011 | -48.92% |
| Sep 30, 2011 | -265.90% |
| Jun 30, 2011 | -18,221.35% |
| Mar 31, 2011 | -12,945.93% |
| Dec 31, 2010 | -14,384.29% |
| Sep 30, 2010 | -15,632.73% |